The impact of initial tumor bulk in DLBCL treated with DA-EPOCH-R vs. R-CHOP: a secondary analysis of alliance/CALGB 50303

被引：0

作者：

Lanier, Claire M. ^{[1
]}

Razavian, Niema B. ^{[1
]}

Smith, Sydney ^{[2
]}

D'Agostino, Ralph B. ^{[2
]}

Hughes, Ryan T. ^{[1
]}

机构：

[1] Wake Forest Univ, Bowman Gray Sch Med, Dept Radiat Oncol, Med Ctr Blvd, Winston Salem, NC 27157 USA

[2] Wake Forest Univ, Bowman Gray Sch Med, Dept Biostat & Data Sci, Winston Salem, NC USA

来源：

LEUKEMIA & LYMPHOMA | 2024年

关键词：

Diffuse large B-cell lymphoma; non-Hodgkin lymphoma; initial tumor bulk; B-CELL LYMPHOMA; ELDERLY-PATIENTS; PROGNOSTIC-SIGNIFICANCE; HODGKIN LYMPHOMA; YOUNG-PATIENTS; CHEMOTHERAPY; RADIOTHERAPY; RITUXIMAB; RADIATION; THERAPY;

D O I：

10.1080/10428194.2024.2393753

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The ideal treatment paradigm for bulky diffuse large B-cell lymphoma (DLBCL) remains uncertain. We investigated the impact of tumor bulk in patients treated with systemic therapy alone through Alliance/CALGB 50303. Data from this trial were obtained from the National Cancer Institute's NCTN/NCORP Data Archive. The study assessed the size of nodal sites and estimated progression-free survival (PFS) using Cox proportional hazards models. Stratified analysis factored in International Prognostic Index (IPI) risk scores. Out of 524 patients, 155 had pretreatment scans. Using a 7.5 cm cutoff, 44% were classified as bulky. Bulk did not significantly impact progression-free survival (PFS), whether measured continuously or at thresholds of >5 or >7.5 cm (p = 0.10-p = 0.99). Stratified analyses by treatment group and IPI risk group were also non-significant. In this secondary analysis, a significant association between bulk and PFS was not identified.

引用

页数：8

共 13 条

[1] Phase III Randomized Study of R-CHOP Versus DA-EPOCH-R and Molecular Analysis of Untreated Diffuse Large B-Cell Lymphoma: CALGB/Alliance 50303
Wilson, Wyndham H.
Sin-Ho, Jung
Pitcher, Brandelyn Nicole
Hsi, Eric D.
Friedberg, Jonathan
Cheson, Bruce
Bartlett, Nancy L.
Smith, Scott
Johnston, Nina Wagner
Kahl, Brad S.
Staudt, Louis M.
Blum, Kristie
Abramson, Jeremy
Press, Oliver W.
Fisher, Richard I.
Richards, Kristy L.
Schoder, Heiko
Chang, Julie E.
Zelenetz, Andrew D.
Leonard, John P.
[J]. BLOOD, 2016, 128 (22)
[2] DA-R-EPOCH vs R-CHOP in DLBCL: How Do We Choose?
Major, Ajay
Smith, Sonali M.
[J]. CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (11) : 698 - +
[3] R-CHOP Vs DA-EPOCH-R for Double-Expressor Lymphoma: A University of California Hematologic Malignancies Consortium Retrospective Analysis
Othman, Tamer
Penaloza, Juan
Zhang, Shiliang
Daniel, Claire E.
Gaut, Daria
Oliai, Caspian
Brem, Elizabeth A.
Baweja, Abinav
Ly, Jane
Reid, Jack
Pinter-Brown, Lauren
Lee, Matthew
Abdulhaq, Haifaa
Tuscano, Joseph
[J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 (10): : E947 - E957
[4] A cost-effectiveness analysis of DA-EPOCH-R versus R-CHOP for the treatment of diffuse large B-cell lymphoma.
Gokul, Ashni
Boyce, Maria
O'Mahony, Deirdre
Bird, Brian Richard
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[5] DA-EPOCH-R VS R-CHOP in Patients with Primary Mediastinal Large B-Cell Lymphoma: Results of Prospective Randomized Ukrainian Multicenter Study
Stepanishyna, Yana
Skrypets, Tetiana
Novosad, Olga
Pastushenko, Ian
Kryachok, Irina
[J]. BLOOD, 2020, 136
[6] Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303
Bartlett, Nancy L.
Wilson, Wyndham H.
Jung, Sin-Ho
Hsi, Eric D.
Maurer, Matthew J.
Pederson, Levi D.
Polley, Mei-Yin C.
Pitcher, Brandelyn N.
Cheson, Bruce D.
Kahl, Brad S.
Friedberg, Jonathan W.
Staudt, Louis M.
Wagner-Johnston, Nina D.
Blum, Kristie A.
Abramson, Jeremy S.
Reddy, Nishitha M.
Winter, Jane N.
Chang, Julie E.
Gopal, Ajay K.
Chadburn, Amy
Mathew, Susan
Fisher, Richard I.
Richards, Kristy L.
Schoder, Heiko
Zelenetz, Andrew D.
Leonard, John P.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (21) : 1790 - +
[7] Real world experience of R-CHOP with or without consolidative radiotherapy vs DA-EPOCH-R in the first-line treatment of primary mediastinal B-cell lymphoma
Li Chan, Esther Hian
Koh, Liang Piu
Lee, Joanne
De Mel, Sanjay
Jeyasekharan, Anand
Liu, Xin
Tang, Tiffany
Lim, Soon Thye
Tao, Miriam
Quek, Richard
Ras, Mohamad Farid Bin Harunal
Lee, Yuh Shan
Diong, Colin
Tan, Daryl
Kim, Seok Jin
Chee, Yen Lin
Poon, Li Mei Michelle
[J]. CANCER MEDICINE, 2019, 8 (10): : 4626 - 4632
[8] DA-EPOCH-R improves the outcome over that of R-CHOP regimen for DLBCL patients below 60 years, GCB phenotype, and those with high-risk IPI, but not for double expressor lymphoma
Xin-Yu Zhang
Jin-Hua Liang
Li Wang
Hua-Yuan Zhu
Wei Wu
Lei Cao
Lei Fan
Jian-Yong Li
Wei Xu
[J]. Journal of Cancer Research and Clinical Oncology, 2019, 145 : 117 - 127
[9] DA-EPOCH-R improves the outcome over that of R-CHOP regimen for DLBCL patients below 60years, GCB phenotype, and those with high-risk IPI, but not for double expressor lymphoma
Zhang, Xin-Yu
Liang, Jin-Hua
Wang, Li
Zhu, Hua-Yuan
Wu, Wei
Cao, Lei
Fan, Lei
Li, Jian-Yong
Xu, Wei
[J]. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2019, 145 (01) : 117 - 127
[10] DA.R-EPOCH Vs. R-CHOP for High-Risk Diffuse Large B-Cell Lymphoma: The Mayo Clinic Florida Experience
Dholaria, Bhagirathbhai
Vishnu, Prakash
Roy, Vivek
Tun, Han W.
Sher, Taimur
Rivera, Candido E.
Ailawadhi, Sikander
Diehl, Nancy
Hodge, David O.
Moreno-Vanegas, Yenni Alejandro
[J]. BLOOD, 2017, 130

← 1 2 →